Ginzler E, Barbosa LSG, D’Cruz D, et al. - This study was undertaken to investigate efficacy and safety of intravenous (IV) belimumab plus standard therapy in patients of self-identified black race. Researchers designed a 52-week multicenter, double-blind, placebo-controlled trial including adults of self-identified black race with active systemic lupus erythematosus (SLE), receiving monthly belimumab 10 mg/kg IV, or placebo, plus standard therapy. A total of 448 patients were included in this study (96.9% female; mean [standard deviation] age: 38.8 [11.42] years). The primary endpoint of this study was not achieved; the study found improvement with belimumab vs placebo, implying that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry.